Ketamine Therapy Market to Reach USD 8.8 Billion by 2034, Growing from USD 2.5 Billion in 2025 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - A once-stigmatized anesthetic is being reframed as mainstream psychiatric care, as a more favorable regulatory environment and a growing body of clinical evidence push ketamine therapy toward the center of mental health treatment. The global ketamine therapy market is valued at USD 2.5 billion in 2025 and is projected to reach USD 8.8 billion by 2034, expanding at a CAGR of 15.00% during the forecast period, according to Strategic Revenue Insights Inc. The findings draw on primary interviews with psychiatrists, ketamine clinic operators, and telehealth providers, combined with secondary research across Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa, led by lead analyst Kamrul Hasan.

Key Takeaways

• The ketamine therapy market is valued at USD 2.5 billion in 2025 and is forecast to reach USD 8.8 billion by 2034, a CAGR of 15.00%.
• Intravenous Ketamine Infusion holds the largest product-type share, while Esketamine Nasal Spray is the fastest-growing segment for its convenience and ease of administration.
• Telehealth integration is expanding access to ketamine therapy, particularly in remote and underserved areas.
• North America leads the market on high demand and healthcare infrastructure, while Asia Pacific is the fastest-growing region amid rising awareness and acceptance.
• Johnson & Johnson, Endo (Par Pharmaceutical), and Hikma Pharmaceuticals are among the leading competitors.

Full report access: https://www.strategicrevenueinsights.com/industry/ketamine-therapy-market

Clinical Evidence and Regulatory Momentum Are Reshaping Mental Health Care

The market's growth is grounded in accumulating clinical evidence: studies have shown ketamine produces rapid antidepressant effects, a particularly meaningful benefit for patients who haven't responded to traditional therapies. That evidence base has spurred greater research and development investment from pharmaceutical companies and healthcare providers, while regulatory bodies in several countries have approved ketamine-based treatments, removing a key barrier to broader adoption.

Delivery innovation is where much of the competitive activity is concentrated. Demand for non-invasive, patient-friendly formats such as nasal sprays and sublingual formulations is rising as patients seek options that can be administered outside traditional clinical settings, prompting companies to invest in new formulations that expand where and how treatment can be delivered.

Access is the third pillar reshaping the market. Telehealth and digital health platforms are extending ketamine therapy's reach into remote and underserved areas, supporting a broader shift toward outpatient and home-based care that is reducing costs and improving patient convenience. That shift is also driving growth in specialized ketamine clinics and telehealth-guided programs, even as companies continue to navigate a regulatory landscape that varies significantly by region and public stigma that can still affect adoption.

Market Segmentation

By Product Type: Intravenous Ketamine Infusion is the most widely used method given its rapid onset and proven effectiveness in clinical settings, while Esketamine Nasal Spray is gaining traction for its convenience and ease of administration as a non-invasive option. Intramuscular Ketamine and Sublingual & Oral Formulations are also gaining popularity as alternative delivery methods offering flexibility and potential for at-home use.

By Indication: Treatment-Resistant Depression is the largest segment, reflecting the condition's high prevalence and the limited effectiveness of traditional antidepressants, while Major Depressive Disorder with Suicidal Ideation is also significant given ketamine's demonstrated promise in reducing suicidal thoughts and behaviors. Post-Traumatic Stress Disorder, Chronic & Neuropathic Pain, Anxiety Disorders, and Substance Use Disorders are also driving growth as research uncovers new therapeutic applications.

By Care Setting: Specialized Ketamine Clinics are the most prominent setting, offering a controlled environment focused on patient safety and treatment adherence, while Hospitals & Psychiatric Facilities also play a significant role as part of comprehensive mental health treatment programs. Supervised At-Home Programs and Telehealth-Guided Programs are emerging as popular options for patients seeking convenience, particularly in remote or underserved areas.

By Distribution Channel: Certified Treatment Centers are the primary channel, equipped with the infrastructure and expertise needed to administer ketamine safely and in compliance with regulatory standards, while Hospital Pharmacies also play a crucial role for patients treated in hospital settings. Specialty Pharmacies are gaining prominence for their personalized services and ability to handle ketamine products' unique storage and handling requirements.

Regional Outlook

North America is the leading regional market, underpinned by high demand and advanced healthcare infrastructure, while Asia Pacific is expected to post the fastest growth as awareness and acceptance of ketamine therapy increase. Latin America, Europe, and the Middle East & Africa round out the report's regional coverage as regulatory environments and healthcare infrastructure continue to develop across those markets.

Competitive Landscape

Johnson & Johnson is a major player through its Esketamine nasal spray, Spravato, one of the first FDA-approved treatments for treatment-resistant depression, backed by strong research and development capabilities and an extensive distribution network. Endo (Par Pharmaceutical) offers a range of ketamine-based products across indications, with a focus on innovation and quality that has helped it build a strong market presence. Hikma Pharmaceuticals is known for its commitment to quality and safety across generic and branded ketamine products, supported by a global distribution network, while Viatris also holds a prominent position with a focus on accessibility and affordability. Emerging players Mindbloom and Compass Pathways are differentiating through telehealth-guided ketamine therapy and psychedelic-therapy research, respectively.

Market Restraints

The regulatory landscape remains complex and varies significantly across regions, requiring companies to navigate stringent approval processes and compliance requirements to bring products to market. Negative public perception and stigma associated with ketamine use also pose a risk to market growth and adoption, alongside competition from alternative mental health therapies that could affect ketamine's market share over time.

Related Reports

https://www.strategicrevenueinsights.com/industry/apoptosis-assay-market

https://www.strategicrevenueinsights.com/industry/artemisinin-combination-therapy-market

https://www.strategicrevenueinsights.com/industry/artificial-organs-bionics-market

https://www.strategicrevenueinsights.com/industry/aseptic-consulting-services-market

https://www.strategicrevenueinsights.com/industry/assisted-reproductive-technology-art-market

Frequently Asked Questions

What is the ketamine therapy market size in 2025?

The global ketamine therapy market was valued at USD 2.5 billion in 2025 and is projected to reach USD 8.8 billion by 2034, growing at a CAGR of 15.00%.

What is driving growth in the ketamine therapy market?

Growth is driven by the increasing prevalence of mental health disorders, growing clinical acceptance of ketamine's rapid antidepressant effects, and expanding access through telehealth platforms.

Which region leads the ketamine therapy market?

North America leads the market due to high demand and advanced healthcare infrastructure, while Asia Pacific is the fastest-growing region amid increasing awareness and acceptance of ketamine therapy.

Who are the top companies in the ketamine therapy market?

Leading companies include Johnson & Johnson, Endo (Par Pharmaceutical), and Hikma Pharmaceuticals, with Viatris also a significant competitor.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases